Pacira Pharmaceuticals CEO to Testify at White House Opioid Crisis Commission Meeting
September 27 2017 - 7:30AM
Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced that
Dave Stack, chairman and chief executive officer, will testify this
afternoon before President Trump’s Commission on Combating Drug
Addiction and the Opioid Crisis. The Commission, led by New Jersey
Governor Chris Christie, was created to study ways to combat and
treat drug abuse, addiction and the opioid crisis.
The meeting, which will be held in Washington, D.C. today from
12:30 p.m. until approximately 2:30 p.m. EDT, will consist of
statements to the Commission from invited government, nonprofit,
and business organizations regarding Innovative Pain Management and
Prevention Measures for Diversion. Discussion related to the issues
raised during the invited statements will follow.
Stack will discuss the critical nature of clinician and patient
access to non-opioid medications that can effectively manage
postsurgical pain while reducing opioid requirements. This is
especially important in light of the opioid epidemic, as research
continues to demonstrate a link between opioid overprescribing in
the surgical setting and the risks of long-term use and/or
accumulation of excess medication in the home, creating a dangerous
potential for diversion or misuse.
Today’s meeting is the third in a series of meetings of the
President's Commission on Combating Drug Addiction and the Opioid
Crisis. It will be open to the public through live streaming on
https://www.whitehouse.gov/live.
About Pacira Pacira Pharmaceuticals, Inc.
(NASDAQ:PCRX) is a specialty pharmaceutical company focused on the
clinical and commercial development of new products that meet the
needs of acute care practitioners and their patients. The company’s
flagship product, EXPAREL® (bupivacaine liposome injectable
suspension), indicated for single-dose infiltration into the
surgical site to produce postsurgical analgesia, was commercially
launched in the United States in April 2012. EXPAREL and two other
products have successfully utilized DepoFoam®, a unique and
proprietary product delivery technology that encapsulates drugs
without altering their molecular structure, and releases them over
a desired period of time. Additional information about Pacira is
available at www.pacira.com.
Company Contact:Pacira Pharmaceuticals, Inc.Susan Mesco, (973)
451-4030susan.mesco@pacira.comMedia Contact:Coyne Public
RelationsAlyssa Schneider, (973) 588-2270aschneider@coynepr.com
Pacira BioSciences (NASDAQ:PCRX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Pacira BioSciences (NASDAQ:PCRX)
Historical Stock Chart
From Sep 2023 to Sep 2024